BBNX Investor Alert: Johnson Fistel Encourages Beta Bionics, Inc. Investors to Contact the Firm Ahead of November 3, 2026 Lead Plaintiff Deadline

Johnson Fistel announced a securities class action against Beta Bionics filed in the U.S. District Court for the Central District of California on behalf of investors who purchased BBNX stock between July 30, 2025 and February 24, 2026, alleging violations of Exchange Act Sections 10(b) and 20(a). The complaint alleges executives made materially false statements about the safety and commercial prospects of the iLet Bionic Pancreas, downplaying FDA quality-management deficiencies, unreported serious adverse events, and a warning letter publicly released on February 24, 2026.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.